Arkema SA (OTCMKTS:ARKAY – Get Free Report) was the recipient of a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 418 shares, a decrease of 75.8% from the July 15th total of 1,729 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,816 shares, the days-to-cover ratio is currently 0.1 days.
Arkema Trading Down 0.0%
Shares of ARKAY opened at $71.81 on Thursday. The stock has a fifty day moving average of $65.98 and a two-hundred day moving average of $67.85. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.64 and a current ratio of 2.25. The company has a market capitalization of $5.46 billion, a PE ratio of 247.62 and a beta of 0.85. Arkema has a fifty-two week low of $56.28 and a fifty-two week high of $79.36.
Arkema (OTCMKTS:ARKAY – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The basic materials company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.12. Arkema had a return on equity of 4.27% and a net margin of 0.67%.The business had revenue of $2.79 billion for the quarter, compared to analysts’ expectations of $2.86 billion. As a group, analysts forecast that Arkema will post 3.67 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Report on Arkema
Arkema Company Profile
Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total’s chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.
Arkema’s operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.
See Also
- Five stocks we like better than Arkema
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Arkema Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arkema and related companies with MarketBeat.com's FREE daily email newsletter.
